Polymyalgia  ||| S:0 E:12 ||| JJ
rheumatica  ||| S:12 E:23 ||| NN
can  ||| S:23 E:27 ||| MD
recur  ||| S:27 E:33 ||| VB
years  ||| S:33 E:39 ||| NNS
after  ||| S:39 E:45 ||| IN
discontinuation  ||| S:45 E:61 ||| NN
of  ||| S:61 E:64 ||| IN
corticosteroid  ||| S:64 E:79 ||| JJ
therapy  ||| S:79 E:87 ||| NN
To  ||| S:87 E:90 ||| TO
describe  ||| S:90 E:99 ||| VB
disease  ||| S:99 E:107 ||| NN
recurrence  ||| S:107 E:118 ||| NN
in  ||| S:118 E:121 ||| IN
polymyalgia  ||| S:121 E:133 ||| JJ
rheumatica ||| S:133 E:143 ||| NN
.  ||| S:143 E:145 ||| .
I  ||| S:145 E:147 ||| PRP
present  ||| S:147 E:155 ||| RB
12  ||| S:155 E:158 ||| CD
patients  ||| S:158 E:167 ||| NNS
with  ||| S:167 E:172 ||| IN
recurring  ||| S:172 E:182 ||| VBG
PMR  ||| S:182 E:186 ||| NNP
from  ||| S:186 E:191 ||| IN
a  ||| S:191 E:193 ||| DT
single  ||| S:193 E:200 ||| JJ
clinical  ||| S:200 E:209 ||| JJ
practice  ||| S:209 E:218 ||| NN
with  ||| S:218 E:223 ||| IN
long-term  ||| S:223 E:233 ||| JJ
clinical  ||| S:233 E:242 ||| JJ
follow-up  ||| S:242 E:252 ||| NN
( ||| S:252 E:253 ||| -LRB-
mean  ||| S:253 E:258 ||| VB
14.3  ||| S:258 E:263 ||| CD
years ||| S:263 E:268 ||| NNS
) ||| S:268 E:269 ||| -RRB-
.  ||| S:269 E:271 ||| .
Despite  ||| S:271 E:279 ||| IN
a  ||| S:279 E:281 ||| DT
disease-free  ||| S:281 E:294 ||| JJ
interval  ||| S:294 E:303 ||| NN
off  ||| S:303 E:307 ||| IN
corticosteroids  ||| S:307 E:323 ||| NN
of  ||| S:323 E:326 ||| IN
2  ||| S:326 E:328 ||| CD
years  ||| S:328 E:334 ||| NNS
or  ||| S:334 E:337 ||| CC
longer ||| S:337 E:343 ||| RB
,  ||| S:343 E:345 ||| ,
these  ||| S:345 E:351 ||| DT
patients  ||| S:351 E:360 ||| NNS
experienced  ||| S:360 E:372 ||| VBD
1  ||| S:372 E:374 ||| CD
overt  ||| S:374 E:380 ||| JJ
recurrence  ||| S:380 E:391 ||| NN
( ||| S:391 E:392 ||| -LRB-
or  ||| S:392 E:395 ||| CC
more ||| S:395 E:399 ||| JJR
)  ||| S:399 E:401 ||| -RRB-
of  ||| S:401 E:404 ||| IN
PMR ||| S:404 E:407 ||| NNP
.  ||| S:407 E:409 ||| .
The  ||| S:409 E:413 ||| DT
course  ||| S:413 E:420 ||| NN
of  ||| S:420 E:423 ||| IN
PMR  ||| S:423 E:427 ||| NNP
is  ||| S:427 E:430 ||| VBZ
not  ||| S:430 E:434 ||| RB
uniformly  ||| S:434 E:444 ||| JJ
monophasic ||| S:444 E:454 ||| NN
,  ||| S:454 E:456 ||| ,
and  ||| S:456 E:460 ||| CC
patient  ||| S:460 E:468 ||| NN
and  ||| S:468 E:472 ||| CC
physician  ||| S:472 E:482 ||| NN
should  ||| S:482 E:489 ||| MD
remain  ||| S:489 E:496 ||| VB
alert  ||| S:496 E:502 ||| JJ
to  ||| S:502 E:505 ||| TO
the  ||| S:505 E:509 ||| DT
possibility  ||| S:509 E:521 ||| NN
of  ||| S:521 E:524 ||| IN
recurring  ||| S:524 E:534 ||| VBG
disease ||| S:534 E:541 ||| NN
.  ||| S:541 E:543 ||| .
